A detailed history of Cedrus LLC transactions in Pfizer Inc stock. As of the latest transaction made, Cedrus LLC holds 15,048 shares of PFE stock, worth $402,383. This represents 0.16% of its overall portfolio holdings.

Number of Shares
15,048
Previous 13,198 14.02%
Holding current value
$402,383
Previous $369 Million 17.93%
% of portfolio
0.16%
Previous 0.18%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$27.7 - $31.39 $51,245 - $58,071
1,850 Added 14.02%
15,048 $435 Million
Q2 2024

Jul 24, 2024

BUY
$25.26 - $29.6 $20,738 - $24,301
821 Added 6.63%
13,198 $369 Million
Q1 2024

Apr 15, 2024

BUY
$25.89 - $29.73 $133,540 - $153,347
5,158 Added 71.45%
12,377 $343 Million
Q4 2023

Jan 26, 2024

SELL
$26.13 - $33.94 $38,750 - $50,333
-1,483 Reduced 17.04%
7,219 $208 Million
Q3 2023

Jan 24, 2024

SELL
$32.09 - $37.51 $1,123 - $1,312
-35 Reduced 0.4%
8,702 $289 Million
Q2 2023

Jan 24, 2024

SELL
$36.12 - $41.79 $16,326 - $18,889
-452 Reduced 4.92%
8,737 $320 Million
Q1 2023

Jan 24, 2024

BUY
$39.39 - $51.28 $46,952 - $61,125
1,192 Added 14.91%
9,189 $375 Million
Q4 2022

Jan 19, 2024

BUY
$41.75 - $54.5 $48,346 - $63,111
1,158 Added 16.93%
7,997 $410 Million
Q3 2022

Jan 19, 2024

BUY
$43.76 - $53.42 $29,012 - $35,417
663 Added 10.74%
6,839 $299 Million
Q2 2022

Jan 19, 2024

BUY
$46.53 - $55.17 $20,100 - $23,833
432 Added 7.52%
6,176 $324 Million
Q1 2022

Jan 19, 2024

SELL
$45.75 - $56.69 $65,605 - $81,293
-1,434 Reduced 19.98%
5,744 $297 Million
Q4 2021

Jan 19, 2024

BUY
$41.32 - $61.25 $296,594 - $439,652
7,178 New
7,178 $424 Million

Others Institutions Holding PFE

About PFIZER INC


  • Ticker PFE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 5,612,349,952
  • Market Cap $150B
  • Description
  • Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...
More about PFE
Track This Portfolio

Track Cedrus LLC Portfolio

Follow Cedrus LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cedrus LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cedrus LLC with notifications on news.